Genetic markers may help predict response to TNF inhibitor therapy in rheumatoid arthritis, potentially leading to more ...

A Janus kinase (JAK) inhibitor outperformed tumor necrosis factor (TNF) blockers for substantially reducing rheumatoid arthritis (RA) symptoms in patients for whom conventional anti-rheumatic ...

can a TNF inhibitor be safely withdrawn once a state ... activity or remission was far out of reach for patients with RA; fortunately, this has changed in the recent past, given the appearance ...

An oral inhibitor would not only have delivery advantages over TNF-α inhibitors ... for much of the bone destruction in rheumatoid arthritis. “It seems like it affects all the partners that ...

ORLANDO -- Major cardiovascular event risk in patients with inflammatory bowel disease (IBD) was no greater with Janus kinase ...

The biologic DMARDs rituximab and abatacept were associated with an increased risk for incident cancers in patients with RA ...

The first type of biologic approved for use in treating RA was designed to target the protein called TNF. These drugs are called anti-TNF biologics, and they block specific steps in the ...

And the final risk that uh we know is associated with TNF inhibitors is the risk of lymphoma. Now, again, it's a very, very small risk and it's complicated because rheumatoid arthritis itself has ...

Medically reviewed by Anita C. Chandrasekaran, MD Methotrexate can cause weight gain in some people. A disease-modifying ...

Rheumatoid arthritis (RA) has been a major growth driver for the pharmaceutical industry over the last 15 years, led by AbbVie’s blockbuster anti-TNF inhibitor treatment Humira (adalimumab).